dng64-car-v
MPNST (Malignant Peripheral Nerve Sheath Tumor)
Cell therapyDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the MPNST (Malignant Peripheral Nerve Sheath Tumor) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Fludarabine St. Jude Children's Research Hospital | Phase 2 | B |
Pembrolizumab Seattle Children's Hospital | Phase 1/2 | CCC |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
View all 23 →
Same molecule, other indications
dng64-car-v is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →